Emotra has learnt that communications from an individual researcher have been disclosed to the financial market. Yesterday and this evening, Emotra has been receiving questions from concerned shareholders about our open, naturalistic, multi-centre study, EUDOR-A. We therefore intend to address this situation through this press release. 190305 - Emotra - PM - Comments on [...]
The Board and CEO of Emotra AB herewith present the year-end report for the financial year 2018. 190221- Year-end report 2018
Emotra AB (“Emotra”) is proud to announce that researchers have demonstrated a further application area for Emotra’s method EDOR®. Researchers at a psychiatric clinic have made a discovery that shows a possible further application of EDOR Test in clinical practice. Their results correlate with recent findings on the biological mechanism behind hyporeactivity. 190205 - [...]
Emotra AB (“Emotra”) is pleased to announce that we have reached an agreement with an Italian research group concerning so-called “research rental”. 181127 - Emotra -Newsletter - Agreement with Italian research group
As Emotra announced in a press release on November 16, a letter of intent has been signed with a London-based psychiatric hospital. The agreement will allow the hospital to evaluate EDOR® in clinical practice for a limited period of time. 181123- Emotra - Newsletter - English hospital gets started
Emotra is proud to announce that Lars-Håkan Thorell, Emotra’s Head of Research and the inventor of EDOR®, in his research for Emotra has demonstrated the biological mechanism behind hyporeactivity. This discovery explains why an increased suicide risk can be identified by EDOR®. 181120- Emotra - PM - Important discoveries in research
Emotra hereby announces that the company has signed a letter of intent with a large, London-based psychiatric hospital. This deal grants the hospital the right to use EDOR® during a limited trial period. The agreement includes 30 tests free of charge, after which Emotra will be compensated for each test analysis. 181116- Emotra - [...]
Emotra has recently held a number of meetings with decision-makers who intend to move forward with testing of EDOR® in their regular clinical practice. The psychiatric caregivers that Emotra has met this autumn have grown increasingly aware of how EDOR test results can supplement the diagnoses they make in their clinical examinations. 181114- Emotra [...]
Today, November 1, 2018, EMOTRA AB (“Emotra”) announced that its Board of Directors have decided on a new rights issue of shares. This rights issue will comprise a maximum of 23,978,953 shares and the public has also been invited to participate. 181101 - Emotra- PM - Issue resolution
The Board of Directors and the CEO of Emotra AB (publ) hereby present the interim report for the first nine months of 2018. 181024 Interim report Jan-Sept 2018